FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-05-11

AUTHORS

Alberto Zaniboni, Enrico Aitini, Sandro Barni, Daris Ferrari, Stefano Cascinu, Vincenzo Catalano, Giuseppe Valmadre, Domenica Ferrara, Enzo Veltri, Claudio Codignola, Roberto Labianca

ABSTRACT

PurposeThe purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen.MethodsPatients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine ± platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study.FOLFIRI consists of irinotecan 180 mg/m2 iv on day 1, leucovorin (l-form) 200 mg/m2 iv on day 1 and 2, 5-FU 400 mg/m2 iv bolus on days 1 and 2, and 5-FU 600 mg/m2 iv by ci for 22 h on days 1 and 2, repeated every 2 weeks. The primary end point was the response rate.ResultsAmong the 50 enrolled patients, 4 partial responses (PR) (8 %) and 14 stable diseases were observed, for a disease control rate of 18/50 (36 %). Forty-one patients (82 %) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5 months, respectively. The 6-month survival rate was 32 %. Grade 3–4 neutropenia and diarrhea occurred in 10 (20 %) and 6 (12 %) patients, respectively.ConclusionThe FOLFIRI regimen showed a modest clinical activity in this quite heavily pretreated patients’ population with locally advanced or metastatic pancreatic cancer with a manageable toxicity profile. More... »

PAGES

1641-1645

Journal

TITLE

Cancer Chemotherapy and Pharmacology

ISSUE

6

VOLUME

69

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1

DOI

http://dx.doi.org/10.1007/s00280-012-1875-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035705631

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22576338


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Camptothecin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415090.9", 
          "name": [
            "Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zaniboni", 
        "givenName": "Alberto", 
        "id": "sg:person.01007271605.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007271605.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, C. Poma Hospital, Mantua, Italy", 
          "id": "http://www.grid.ac/institutes/grid.413174.4", 
          "name": [
            "Medical Oncology Unit, C. Poma Hospital, Mantua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aitini", 
        "givenName": "Enrico", 
        "id": "sg:person.01227625605.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227625605.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Treviglio-Caravaggio Hospital, Treviglio, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Unit, Treviglio-Caravaggio Hospital, Treviglio, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barni", 
        "givenName": "Sandro", 
        "id": "sg:person.0645550356.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, S. Paolo Hospital, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415093.a", 
          "name": [
            "Medical Oncology Unit, S. Paolo Hospital, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrari", 
        "givenName": "Daris", 
        "id": "sg:person.010637300302.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010637300302.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Universit\u00e0 Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy", 
          "id": "http://www.grid.ac/institutes/grid.7010.6", 
          "name": [
            "Medical Oncology Unit, Universit\u00e0 Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cascinu", 
        "givenName": "Stefano", 
        "id": "sg:person.01157163143.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157163143.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy", 
          "id": "http://www.grid.ac/institutes/grid.476115.0", 
          "name": [
            "Medical Oncology Unit, Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Catalano", 
        "givenName": "Vincenzo", 
        "id": "sg:person.0645354261.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645354261.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology DH, Ospedale di Sondalo, Sondalo, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology DH, Ospedale di Sondalo, Sondalo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valmadre", 
        "givenName": "Giuseppe", 
        "id": "sg:person.0643750241.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643750241.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy", 
          "id": "http://www.grid.ac/institutes/grid.416325.7", 
          "name": [
            "Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrara", 
        "givenName": "Domenica", 
        "id": "sg:person.01266456053.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266456053.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Ospedale Don Luigi di Liegro, Gaeta, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Medical Oncology Unit, Ospedale Don Luigi di Liegro, Gaeta, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Veltri", 
        "givenName": "Enzo", 
        "id": "sg:person.0775351634.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775351634.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Fondazione Poliambulanza, Brescia, Italy", 
          "id": "http://www.grid.ac/institutes/grid.415090.9", 
          "name": [
            "Department of Surgery, Fondazione Poliambulanza, Brescia, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Codignola", 
        "givenName": "Claudio", 
        "id": "sg:person.01026312041.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026312041.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy", 
          "id": "http://www.grid.ac/institutes/grid.460094.f", 
          "name": [
            "Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Labianca", 
        "givenName": "Roberto", 
        "id": "sg:person.01070501201.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070501201.50"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-008-0839-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039934508", 
          "https://doi.org/10.1007/s00280-008-0839-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605374", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010346465", 
          "https://doi.org/10.1038/sj.bjc.6605374"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-05-11", 
    "datePublishedReg": "2012-05-11", 
    "description": "PurposeThe purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen.MethodsPatients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine\u00a0\u00b1\u00a0platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study.FOLFIRI consists of irinotecan 180\u00a0mg/m2 iv on day 1, leucovorin (l-form) 200\u00a0mg/m2 iv on day 1 and 2, 5-FU 400\u00a0mg/m2 iv bolus on days 1 and 2, and 5-FU 600\u00a0mg/m2 iv by ci for 22\u00a0h on days 1 and 2, repeated every 2\u00a0weeks. The primary end point was the response rate.ResultsAmong the 50 enrolled patients, 4 partial responses (PR) (8\u00a0%) and 14 stable diseases were observed, for a disease control rate of 18/50 (36\u00a0%). Forty-one patients (82\u00a0%) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5\u00a0months, respectively. The 6-month survival rate was 32\u00a0%. Grade 3\u20134 neutropenia and diarrhea occurred in 10 (20\u00a0%) and 6 (12\u00a0%) patients, respectively.ConclusionThe FOLFIRI regimen showed a modest clinical activity in this quite heavily pretreated patients\u2019 population with locally advanced or metastatic pancreatic cancer with a manageable toxicity profile.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00280-012-1875-1", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "69"
      }
    ], 
    "keywords": [
      "second-line chemotherapy", 
      "first-line chemotherapy", 
      "metastatic pancreatic cancer", 
      "m2 IV", 
      "day 1", 
      "pancreatic cancer", 
      "FOLFIRI regimen", 
      "partial response", 
      "gemcitabine-based regimen", 
      "multicenter phase II study", 
      "m2 IV bolus", 
      "modest clinical activity", 
      "primary end point", 
      "disease control rate", 
      "manageable toxicity profile", 
      "advanced pancreatic cancer", 
      "phase II study", 
      "measurable disease", 
      "RECIST criteria", 
      "stable disease", 
      "metastatic disease", 
      "overall survival", 
      "control rate", 
      "cisplatin/", 
      "clinical activity", 
      "grade 3", 
      "toxicity profile", 
      "response rate", 
      "patients", 
      "chemotherapy", 
      "survival rate", 
      "regimen", 
      "end point", 
      "cancer", 
      "disease", 
      "FOLFIRI", 
      "PurposeThe purpose", 
      "present study", 
      "MethodsPatients", 
      "tolerability", 
      "neutropenia", 
      "gemcitabine", 
      "diarrhea", 
      "bolus", 
      "study", 
      "weeks", 
      "months", 
      "survival", 
      "rate", 
      "activity", 
      "failure", 
      "population", 
      "response", 
      "criteria", 
      "profile", 
      "cis", 
      "purpose", 
      "point", 
      "platinoids", 
      "leucovorin (l-form) 200", 
      "iv bolus", 
      "GISCAD multicenter phase II study", 
      "II study"
    ], 
    "name": "FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study", 
    "pagination": "1641-1645", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035705631"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00280-012-1875-1"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22576338"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00280-012-1875-1", 
      "https://app.dimensions.ai/details/publication/pub.1035705631"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_576.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00280-012-1875-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00280-012-1875-1'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      22 PREDICATES      103 URIs      93 LITERALS      19 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00280-012-1875-1 schema:about N09aaa7e87ecf434a91b5617039f90d72
2 N0bae87d528a846d5ab5a2cc4677c800b
3 N1c0a57ec7690400bae6e8e5be9b0aced
4 N3f0887c9b6714766a66b3ccd5b6cfd81
5 N423b523b55a149beb4d872a693f8d1c4
6 N48eb3628ce2e4df98a1464eff4963bdb
7 N49b952ebd7384d78bbc85c13a5e4501d
8 N7c57b66a95954652bf68cde714a386c6
9 N9a9a6cddf5bb4852970a49ca5695a1ad
10 Na03f61dc9e914f6385b42d8e1f37a68e
11 Na8afbb2e3e5541b89ba106e224aee8e7
12 Nd041399c066648768a586213cada1444
13 anzsrc-for:11
14 anzsrc-for:1112
15 schema:author N4c25710bddc74f17a21b2ab08bb5bfa8
16 schema:citation sg:pub.10.1007/s00280-008-0839-y
17 sg:pub.10.1038/sj.bjc.6605374
18 schema:datePublished 2012-05-11
19 schema:datePublishedReg 2012-05-11
20 schema:description PurposeThe purpose of the present study was to evaluate the activity and the tolerability of the FOLFIRI regimen, administered as second-line chemotherapy in patients with locally advanced or metastatic pancreatic cancer after the failure of a gemcitabine-based regimen.MethodsPatients with locally advanced/metastatic disease who received a first-line chemotherapy (one line only) with gemcitabine ± platinoid (cisplatin, oxaliplatin) and who had measurable disease conform with the RECIST criteria were eligible for the study.FOLFIRI consists of irinotecan 180 mg/m2 iv on day 1, leucovorin (l-form) 200 mg/m2 iv on day 1 and 2, 5-FU 400 mg/m2 iv bolus on days 1 and 2, and 5-FU 600 mg/m2 iv by ci for 22 h on days 1 and 2, repeated every 2 weeks. The primary end point was the response rate.ResultsAmong the 50 enrolled patients, 4 partial responses (PR) (8 %) and 14 stable diseases were observed, for a disease control rate of 18/50 (36 %). Forty-one patients (82 %) have been pretreated with cisplatin/oxaliplatin+gemcitabine as first-line chemotherapy. The median progression-free and overall survivals were 3.2 and 5 months, respectively. The 6-month survival rate was 32 %. Grade 3–4 neutropenia and diarrhea occurred in 10 (20 %) and 6 (12 %) patients, respectively.ConclusionThe FOLFIRI regimen showed a modest clinical activity in this quite heavily pretreated patients’ population with locally advanced or metastatic pancreatic cancer with a manageable toxicity profile.
21 schema:genre article
22 schema:inLanguage en
23 schema:isAccessibleForFree false
24 schema:isPartOf N42b9cda7c59f4c2c9e2e140e103d93a4
25 Nfca8ff7ff0b3403994b1e29d21545192
26 sg:journal.1088364
27 schema:keywords FOLFIRI
28 FOLFIRI regimen
29 GISCAD multicenter phase II study
30 II study
31 MethodsPatients
32 PurposeThe purpose
33 RECIST criteria
34 activity
35 advanced pancreatic cancer
36 bolus
37 cancer
38 chemotherapy
39 cis
40 cisplatin/
41 clinical activity
42 control rate
43 criteria
44 day 1
45 diarrhea
46 disease
47 disease control rate
48 end point
49 failure
50 first-line chemotherapy
51 gemcitabine
52 gemcitabine-based regimen
53 grade 3
54 iv bolus
55 leucovorin (l-form) 200
56 m2 IV
57 m2 IV bolus
58 manageable toxicity profile
59 measurable disease
60 metastatic disease
61 metastatic pancreatic cancer
62 modest clinical activity
63 months
64 multicenter phase II study
65 neutropenia
66 overall survival
67 pancreatic cancer
68 partial response
69 patients
70 phase II study
71 platinoids
72 point
73 population
74 present study
75 primary end point
76 profile
77 purpose
78 rate
79 regimen
80 response
81 response rate
82 second-line chemotherapy
83 stable disease
84 study
85 survival
86 survival rate
87 tolerability
88 toxicity profile
89 weeks
90 schema:name FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study
91 schema:pagination 1641-1645
92 schema:productId N18cf5f8788074cfdb95ff14312354e5b
93 N8a6e51da82f64811933a41ddf70b316b
94 Ne6e5b088f8e649ee8949cac771cff1f4
95 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035705631
96 https://doi.org/10.1007/s00280-012-1875-1
97 schema:sdDatePublished 2021-11-01T18:18
98 schema:sdLicense https://scigraph.springernature.com/explorer/license/
99 schema:sdPublisher Nb1633cb4c5774a23a82a12faf384da9e
100 schema:url https://doi.org/10.1007/s00280-012-1875-1
101 sgo:license sg:explorer/license/
102 sgo:sdDataset articles
103 rdf:type schema:ScholarlyArticle
104 N09aaa7e87ecf434a91b5617039f90d72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Pancreatic Neoplasms
106 rdf:type schema:DefinedTerm
107 N0bae87d528a846d5ab5a2cc4677c800b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Aged, 80 and over
109 rdf:type schema:DefinedTerm
110 N0e09c2c9163e47fa81b6f80a28f5f951 rdf:first sg:person.01157163143.28
111 rdf:rest Nda1622ae55d04afe9082cf6313d816e2
112 N1090e6f7a1d44d588af5f0e86b43b80c rdf:first sg:person.01227625605.45
113 rdf:rest N51dded628fb34fbf8bf1592fd0e902e6
114 N18cf5f8788074cfdb95ff14312354e5b schema:name dimensions_id
115 schema:value pub.1035705631
116 rdf:type schema:PropertyValue
117 N1c0a57ec7690400bae6e8e5be9b0aced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Camptothecin
119 rdf:type schema:DefinedTerm
120 N3f0887c9b6714766a66b3ccd5b6cfd81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Humans
122 rdf:type schema:DefinedTerm
123 N4106cf96a8d74746bc6bf200ffae6d75 rdf:first sg:person.010637300302.03
124 rdf:rest N0e09c2c9163e47fa81b6f80a28f5f951
125 N423b523b55a149beb4d872a693f8d1c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Antineoplastic Combined Chemotherapy Protocols
127 rdf:type schema:DefinedTerm
128 N42b9cda7c59f4c2c9e2e140e103d93a4 schema:volumeNumber 69
129 rdf:type schema:PublicationVolume
130 N48eb3628ce2e4df98a1464eff4963bdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Middle Aged
132 rdf:type schema:DefinedTerm
133 N49b952ebd7384d78bbc85c13a5e4501d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Survival Rate
135 rdf:type schema:DefinedTerm
136 N4c25710bddc74f17a21b2ab08bb5bfa8 rdf:first sg:person.01007271605.65
137 rdf:rest N1090e6f7a1d44d588af5f0e86b43b80c
138 N51dded628fb34fbf8bf1592fd0e902e6 rdf:first sg:person.0645550356.01
139 rdf:rest N4106cf96a8d74746bc6bf200ffae6d75
140 N5cfc257377104e06b8aaeee4bbb830a0 rdf:first sg:person.01070501201.50
141 rdf:rest rdf:nil
142 N75580668c5dd4bb0926f2421234ef17c rdf:first sg:person.0643750241.92
143 rdf:rest Nadb42a0f23194178834a5ad9bda6ea48
144 N7c57b66a95954652bf68cde714a386c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Fluorouracil
146 rdf:type schema:DefinedTerm
147 N8720955b06e24d568a11e6b6f0783782 rdf:first sg:person.0775351634.55
148 rdf:rest Nbb9f0daad2f8440891f3e71b4f1432a4
149 N8a6e51da82f64811933a41ddf70b316b schema:name pubmed_id
150 schema:value 22576338
151 rdf:type schema:PropertyValue
152 N9a9a6cddf5bb4852970a49ca5695a1ad schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Aged
154 rdf:type schema:DefinedTerm
155 Na03f61dc9e914f6385b42d8e1f37a68e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 Na8afbb2e3e5541b89ba106e224aee8e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Leucovorin
160 rdf:type schema:DefinedTerm
161 Nadb42a0f23194178834a5ad9bda6ea48 rdf:first sg:person.01266456053.12
162 rdf:rest N8720955b06e24d568a11e6b6f0783782
163 Nb1633cb4c5774a23a82a12faf384da9e schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 Nbb9f0daad2f8440891f3e71b4f1432a4 rdf:first sg:person.01026312041.38
166 rdf:rest N5cfc257377104e06b8aaeee4bbb830a0
167 Nd041399c066648768a586213cada1444 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Male
169 rdf:type schema:DefinedTerm
170 Nda1622ae55d04afe9082cf6313d816e2 rdf:first sg:person.0645354261.22
171 rdf:rest N75580668c5dd4bb0926f2421234ef17c
172 Ne6e5b088f8e649ee8949cac771cff1f4 schema:name doi
173 schema:value 10.1007/s00280-012-1875-1
174 rdf:type schema:PropertyValue
175 Nfca8ff7ff0b3403994b1e29d21545192 schema:issueNumber 6
176 rdf:type schema:PublicationIssue
177 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
178 schema:name Medical and Health Sciences
179 rdf:type schema:DefinedTerm
180 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
181 schema:name Oncology and Carcinogenesis
182 rdf:type schema:DefinedTerm
183 sg:journal.1088364 schema:issn 0344-5704
184 1432-0843
185 schema:name Cancer Chemotherapy and Pharmacology
186 schema:publisher Springer Nature
187 rdf:type schema:Periodical
188 sg:person.01007271605.65 schema:affiliation grid-institutes:grid.415090.9
189 schema:familyName Zaniboni
190 schema:givenName Alberto
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007271605.65
192 rdf:type schema:Person
193 sg:person.01026312041.38 schema:affiliation grid-institutes:grid.415090.9
194 schema:familyName Codignola
195 schema:givenName Claudio
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01026312041.38
197 rdf:type schema:Person
198 sg:person.010637300302.03 schema:affiliation grid-institutes:grid.415093.a
199 schema:familyName Ferrari
200 schema:givenName Daris
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010637300302.03
202 rdf:type schema:Person
203 sg:person.01070501201.50 schema:affiliation grid-institutes:grid.460094.f
204 schema:familyName Labianca
205 schema:givenName Roberto
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070501201.50
207 rdf:type schema:Person
208 sg:person.01157163143.28 schema:affiliation grid-institutes:grid.7010.6
209 schema:familyName Cascinu
210 schema:givenName Stefano
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01157163143.28
212 rdf:type schema:Person
213 sg:person.01227625605.45 schema:affiliation grid-institutes:grid.413174.4
214 schema:familyName Aitini
215 schema:givenName Enrico
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227625605.45
217 rdf:type schema:Person
218 sg:person.01266456053.12 schema:affiliation grid-institutes:grid.416325.7
219 schema:familyName Ferrara
220 schema:givenName Domenica
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01266456053.12
222 rdf:type schema:Person
223 sg:person.0643750241.92 schema:affiliation grid-institutes:None
224 schema:familyName Valmadre
225 schema:givenName Giuseppe
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643750241.92
227 rdf:type schema:Person
228 sg:person.0645354261.22 schema:affiliation grid-institutes:grid.476115.0
229 schema:familyName Catalano
230 schema:givenName Vincenzo
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645354261.22
232 rdf:type schema:Person
233 sg:person.0645550356.01 schema:affiliation grid-institutes:None
234 schema:familyName Barni
235 schema:givenName Sandro
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645550356.01
237 rdf:type schema:Person
238 sg:person.0775351634.55 schema:affiliation grid-institutes:None
239 schema:familyName Veltri
240 schema:givenName Enzo
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775351634.55
242 rdf:type schema:Person
243 sg:pub.10.1007/s00280-008-0839-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1039934508
244 https://doi.org/10.1007/s00280-008-0839-y
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/sj.bjc.6605374 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010346465
247 https://doi.org/10.1038/sj.bjc.6605374
248 rdf:type schema:CreativeWork
249 grid-institutes:None schema:alternateName Medical Oncology DH, Ospedale di Sondalo, Sondalo, Italy
250 Medical Oncology Unit, Ospedale Don Luigi di Liegro, Gaeta, Italy
251 Medical Oncology Unit, Treviglio-Caravaggio Hospital, Treviglio, Italy
252 schema:name Medical Oncology DH, Ospedale di Sondalo, Sondalo, Italy
253 Medical Oncology Unit, Ospedale Don Luigi di Liegro, Gaeta, Italy
254 Medical Oncology Unit, Treviglio-Caravaggio Hospital, Treviglio, Italy
255 rdf:type schema:Organization
256 grid-institutes:grid.413174.4 schema:alternateName Medical Oncology Unit, C. Poma Hospital, Mantua, Italy
257 schema:name Medical Oncology Unit, C. Poma Hospital, Mantua, Italy
258 rdf:type schema:Organization
259 grid-institutes:grid.415090.9 schema:alternateName Department of Surgery, Fondazione Poliambulanza, Brescia, Italy
260 Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
261 schema:name Department of Surgery, Fondazione Poliambulanza, Brescia, Italy
262 Medical Oncology Unit, Fondazione Poliambulanza, Via Bissolati 57, 25124, Brescia, Italy
263 rdf:type schema:Organization
264 grid-institutes:grid.415093.a schema:alternateName Medical Oncology Unit, S. Paolo Hospital, Milan, Italy
265 schema:name Medical Oncology Unit, S. Paolo Hospital, Milan, Italy
266 rdf:type schema:Organization
267 grid-institutes:grid.416325.7 schema:alternateName Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy
268 schema:name Medical Oncology Unit, Ospedale San Carlo, Potenza, Italy
269 rdf:type schema:Organization
270 grid-institutes:grid.460094.f schema:alternateName Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
271 schema:name Medical Oncology Unit, Ospedali Riuniti, Bergamo, Italy
272 rdf:type schema:Organization
273 grid-institutes:grid.476115.0 schema:alternateName Medical Oncology Unit, Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy
274 schema:name Medical Oncology Unit, Ospedali Riuniti Marche Nord, Presidio San Salvatore, Pesaro, Italy
275 rdf:type schema:Organization
276 grid-institutes:grid.7010.6 schema:alternateName Medical Oncology Unit, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy
277 schema:name Medical Oncology Unit, Università Politecnica delle Marche, Ospedali Riuniti di Ancona, Ancona, Italy
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...